Irvine, CA – November 7, 2024 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug refractory paroxysmal Atrial Fibrillation (AFib). More @Wikipedia
Get the latest news about Johnson & Johnson from the top news sites, aggregators and blogs. Also included are videos, photos, and websites related to Johnson & Johnson.
Hover over any link to get a description of the article. Please note that search keywords are sometimes hidden within the full article and don't appear in the description or title.